Biomarkers of neurological injury can potentially predict postoperative cognitive dysfunction. We aimed to identify whether classical neuronal damage-specific biomarkers, including brain fatty acid-binding protein, neuron-specific enolase and S100 calcium-binding protein b, as well as plasma-free haemoglobin concentration as a measure of haemolysis, could be used to predict the risk of long-term cognitive decline after coronary artery bypass grafting with or without cardiopulmonary bypass. We assessed cognitive function using the CogState brief computerised cognitive test battery at 3 months and at 15 months after surgery. Blood samples were obtained pre-operatively, after sternal closure, and at 6 h and 24 h postoperatively. We found signs of cognitive decline at 3 months in 15 of 57 patients (26%), and in 13 of 48 patients (27%) at 15 months. Brain fatty acid-binding protein was already significantly higher before surgery in patients with postoperative cognitive dysfunction at 15 months, with pre-operative plasma levels of 22.8 (8.3-33.0 [0-44.6]) pg.ml À1 compared with 9.7 (3.9-17.3 [0-49.0]) pg.ml À1 in patients without cognitive dysfunction. This biomarker remained significantly higher in patients with cognitive decline throughout the entire postoperative period. At 3 months after surgery, high levels of plasma-free haemoglobin at sternal closure were associated with a negative influence on cognitive performance, as were high baseline scores on neuropsychological tests, whereas a higher level of education proved to beneficially influence cognitive outcome. We found that postoperative cognitive dysfunction at 3 months was associated with cognitive decline at 15 months after surgery, and served as a valuable prognostic factor for declines in individual cognitive performance one year later. Classical neuronal injury-related biomarkers were of no clear prognostic value.
Introduction
Postoperative cognitive dysfunction (POCD) is a common complication after cardiac surgery. At hospital discharge, 30-80% of patients have been shown to have POCD, and after 6 months, 20-40% of patients still experience cognitive impairment [1, 2] . In some patients, impairment lasts for a year or longer [3] . Among affected patients, cognitive function tests performed before and after surgery revealed subtle deteriorations in working memory, attention, psychomotor speed and learning abilities. The impact of POCD is significant, because it is associated with prolonged hospitalisation, higher rate of discharge to facilities for long-term care and increased morbidity and mortality, compared with patients without POCD [4] .
Risk factors for POCD include: advanced age; poor education; and increased invasiveness of the surgical procedure [5] . Cardiac surgery is known to be associated with a higher incidence of POCD when compared with non-cardiac surgery [6] . Cardiopulmonary bypass has been claimed to be responsible for this higher incidence. Aspects of bypass claimed to be involved in neuronal injury are: micro-emboli; hypotension; issues related to management of hypothermia, such as fast rewarming; and increased expression of inflammatory and vasoactive molecules induced by shear stress associated with non-pulsatile flow during bypass [7, 8] . Current evidence, however, suggests that long-term cognitive dysfunction among patients undergoing cardiac surgery with bypass is not worse than that of patients undergoing cardiac surgery without bypass [8, 9] , or that of non-surgical control patients with coronary artery disease [10] . It thus appears that POCD cannot be attributed solely to bypass.
The aetiology of POCD is still not fully understood, but given the complexity of the various physiological disturbances associated with surgery and anaesthesia for cardiac surgery, and their potential for multiple effects on postoperative cerebral function, it is likely that multiple factors, including micro-emboli, neuroinflammation and the potentially neurotoxic effects of anaesthetic agents [11] , contribute to the pathophysiology of neurological injury resulting in POCD.
Biomarkers of neurological injury can potentially predict postoperative cognitive outcome. Neuron-specific enolase (NSE) and astroglial S100 Calcium-binding protein b (S100b) are frequently investigated in association with cognitive decline, but only the latter appears to be associated with POCD [12] , although a thorough meta-analysis could not confirm this [13] . A confounding factor is that while these biomarkers are released in response to injury, it is still not known whether they are released in response to injurious, neuroprotective or neuronal repair processes. There is a clear need for biomarkers predictive of neurological damage.
Erythrocyte lysis results in the release of important vasoactive agents that have not yet been investigated in relation to POCD. In this study, we measured free haemoglobin (PfHb) as a marker for erythrocyte lysis and neuronal injury-related biomarkers in pre-and postoperative plasma samples to compare their ability to predict POCD. Neuronal injury biomarkers assayed included brain fatty acid-binding protein (BFABP), NSE and S100b.
Thus far, none of the abovementioned biomarkers have been shown to have sufficient sensitivity and specificity as predictors of neurological dysfunction after cardiac surgery to be able to serve as a gold standard. Many investigators advocate the analysis of a combination of two or more plasma biomarkers, to get a realistic insight into current and future neurological status, by combining information and thus increasing sensitivity [14] . The aim of the current study was to determine whether classical neuronal damage-specific biomarkers and PfHb, as a measure of haemolysis, could be used to predict the risk of long-term POCD after coronary artery bypass surgery, in relation to commonly described risk factors.
Methods
We undertook a secondary analysis of data from a published randomised clinical trial that investigated the differences in the incidence and severity of cerebral oxygen desaturation during coronary artery bypass surgery with or without bypass [15] . Study patients underwent coronary artery bypass surgery at the University Medical Centre Groningen, the Netherlands, between June 2011 and May 2012. We obtained ethical approval from the institutional ethical committee.
Details of the study methods, such as patient inclusion criteria, anaesthetic and surgical procedure, and postoperative care have been described elsewhere [15] . We recorded baseline characteristics including age, sex, body mass index (BMI), education, a history of transient ischaemic attack (TIA), diabetes mellitus and smoking. Intra-and postoperative variables included: duration of procedure; bypass and aortic cross-clamp time; postoperative Nt-pro BNP; and high-sensitivity cardiac troponin T (hs-TnT) after 24 h.
We assessed cognitive function using the CogState brief computerised cognitive test battery involving playing cards (Cogstate Ltd, Melbourne, Vic, Australia). The test battery comprised a Detection Task, Identification Task, One Card Learning Task and One Back Task [16] . The Detection Task measured psychomotor speed, as the subject was required to press a 'Yes' button on the mouse or keyboard, as soon as a card turned face-upward. The Identification Task measured visual attention, by requiring a quick response when a specific card appeared face-upwards ('Yes' button) or not ('No' button). The One Card Learning Task assessed visual learning and memory, as the subject was required to indicate (by means of button presses) whether a card had been shown previously in the task. Finally, we used the One Back Memory Task to assess working memory, as the subject was required to indicate whether a card being displayed was the same as the previously displayed card. In the Detection and Identification Tasks, performance speed (mean of the log10 transformed reaction times for correct responses) was used as the outcome variable, and in the One Card Learning and One Back, performance accuracy was quantified as the arcsine of the square root of the proportion of correct responses.
These cognitive tests were performed twice on the day before the surgical procedure; the first test to minimise practice effects, followed by the baseline test. Postoperative tests were performed at 4 days, 3 months and 15 months after surgery. The test battery took approximately 15 min to complete. Each task was explained to the participants by an investigator using standardised instructions. All cognitive function scores were standardised according to normative testretest variability data from age-matched controls (normative data provided by the software vendor). Thus, a standardised score higher than 100 indicated a better than average score compared with the age-matched population. For each postoperative cognitive test, a standardised change Z-score was calculated, from the difference between the postoperative and baseline score. The Z-scores of the individual tasks were summed to generate a composite standardised change score. Postoperative cognitive dysfunction was defined as a Z-score < À2 in two or more individual tasks, or a composite Z-score of < À2 [17] . Long-term POCD was defined as POCD at 15 months postoperatively.
We obtained blood samples (5 ml whole blood) pre-operatively, after sternum closure, at 6 h and at 24 h postoperatively. We assayed neuronal damage biomarkers in one batch after the last study patient was discharged from hospital. Enzyme-linked immunosorbent assay was used to determine BFABP, NSE and S100b. For BFABP, we used a specific monoclonal capture antibodies clone 13-5 and rabbit polyclonal detection antibody (Haemoscan, Groningen, the Netherlands). Neuron-specific enolase was determined using monoclonal capture and biotinylated detection antibodies from Hytest (Hytest, Turku, Finland), followed by streptavidin-linked HRP. Astroglial S100 Calcium-binding protein b was determined using clone 1B2 monoclonal antibody as the capture (Abnova, Taipei, Taiwan) and biotinylated clone 8B10 as the detection antibody.
To assess the degree of haemolysis, we determined the presence of free haemoglobin in plasma by spectrophotometric haemoglobin assay. First, blood samples were diluted in sodium carbonate. Thereafter, we performed measurements of optical density (OD*) at 415 nm, 450 nm and 380 nm according to the formula: OD* = (2 9 OD415)ÀOD450-OD380. A linear standard curve of 5 mg.ml À1 Hb was used to calculate the PfHb concentration of OD*. All plasma biomarker levels were corrected for postoperative haemodilution as follows:
Corrected level = plasma levelÂ ðHb at 24 h after surgery/pre-operative Hb):
We performed all statistical analyses with SPSS version 22 (IBM Inc., Chicago, IL, USA). Distribution of variables was assessed by the Kolmogorov-Smirnov test. Categorical variables were tested using a chisquare test. We performed univariate regression analysis to identify potential factors for a multiple linear regression analysis (variables were included when the univariate p was < 0.200). A backward method multivariate linear regression analysis was used to assess the predictive value of variables in the equation with a criterion F-to-remove ≥ 0.100. Between-group differences in independent continuous data were analysed using Mann-Whitney U-tests. Related samples were tested using the Wilcoxon signed-rank test. We performed Cox regression analysis to investigate the effect of POCD Z-score on postoperative mortality. We considered p < 0.05 to be statistically significant.
Results
Data were available from 57 patients, 28 who underwent surgery with bypass and 29 without bypass. Cognitive function was assessed at 3 months in 57 patients and at 15 months in 48 patients postoperatively. Signs of POCD were found in 15 of 57 patients (26%) at 3 months, and in 13 of 48 patients (27%) at 15 months. Three patients died during follow-up. All three had undergone surgery with bypass, and all showed evidence of POCD at 3 months. Postoperative mortality was significantly associated with POCD Z-score at 3 months, hazard ratio 0.66 (0.49-0.88; p = 0.006).
Characteristics of the 49 patients for whom cognitive test results were available at 15 months are summarised in Table 1 . High baseline tests scores of Detection and Identification tasks were significantly associated with POCD development, together with a longer duration of surgery, compared with patients without long-term POCD. With regard to the characteristics of patients with and without POCD at 3 months after surgery, on-pump surgery, a lower educational level and above average baseline performance of Detection and Identification tasks were associated with POCD development (Supporting information Table S1 ). Figure 1 shows the composite standardised cognitive function change scores, relative to baseline, measured at 4-6 days, 3 months and 15 months after surgery. A distinction was made based on the presence of signs for POCD at 15 months. Red solid lines indicate patients who fulfilled the criteria for long-term POCD (i.e. standardised change score < À2 for two or more tests, or composite Z-score < À2 at 15 months). Black dashed lines indicate patients without long-term POCD. Interestingly, patients with the lowest change scores at 4-6 days after surgery continued to score , respectively, p = 0.031). The relationship between POCD at 15 months and classical neuronal damage-specific biomarkers was analysed using univariate regression analysis (Table 2) . This revealed an association between elevated BFABP levels during the pre-operative phase, after sternal closure and at 24 h postoperatively, and POCD. Astroglial S100 calcium-binding protein b at sternal closure was also associated with POCD. Furthermore, PfHb at sternal closure, as well as at six h after the procedure, was associated with the occurrence of POCD at 15 months. Moreover, we found a relation between hs-TnT at 24 h, and POCD. Before performing the regression analyses, we assessed all factors for multicollinearity. For all biomarkers, the measurements at different time points correlated with each other. Therefore, only plasma levels of S100b, BFABP and PfHb at sternal closure were used in the multivariate regression analysis, as these appeared to have biggest impact on POCD based on their individual b.
These biomarkers were included in a multivariate regression analysis to assess the association with POCD at both 3 months and 15 months ( Table 3) . The following demographic characteristics were also included in this analysis: use of cardiopulmonary bypass; age; educational level; baseline standardised POCD test scores; and change score at the previous testing moment (i.e. scores at 4-6 days vs. 3 months, and at 3 months vs. 15 months). High PfHb levels at sternal closure and high baseline POCD scores were associated with worse cognitive function scores at 3 months, whereas higher education status was associated with better cognitive function at 3 months. High hs-TnT values at 24 h and low POCD composite Zscores at 3 months were associated with POCD at 15 months. None of the classical neuronal damagespecific biomarkers were significantly associated with POCD either short-or long-term.
At sternal closure, there was a significant increase in PfHb in patients who underwent surgery with or without bypass, with significantly higher values if bypass was used (Fig. 3a) . Plasma-free haemoglobin levels reached normal baseline levels within 6 h after surgery. Scatterplots of PfHb plasma level and POCD Z-score at 3 months (Fig. 3b) and 15 months (Fig. 3c) show the inverse correlation between high plasma PfHb throughout time, and cognitive function.
Discussion
We found that of all the biomarkers studied, only PfHb was associated with POCD at 3 months after cardiac surgery. Regarding long-term POCD, we found an association between cognitive deficits and increased BFABP and PfHb plasma levels at sternal closure, but only in univariate analyses.
Three important features regarding POCD throughout time were apparent (Fig. 1) . Firstly, in the acute phase after surgery, the standardised change scores were widely variable. Some patients demonstrated little change when compared with baseline function, whereas others showed improvements in cognitive performance, while others performed far worse than at baseline. Secondly, after 3 months, it appeared Figure 2 Biomarker levels divided by the development of POCD at 15 months after surgery. Blood samples from patients without POCD( ⃝) and patients with POCD (•) were taken pre-operatively, at sternal closure, after 6 h and after 24 h. Error bars indicate SD. Difference between plasma levels compared with baseline are indicated with */** for p < 0.05 and p < 0.01, respectively. Likewise, significant differences in POCD development are indicated with +/++ for p < 0.05 and p < 0.01. that most of the damage had been done. Almost all patients without long-term POCD, who had signs of POCD in the acute phase, had full recovery of cognitive function at 3 months. On the other hand, most patients with POCD at 3 months continued to show symptoms one year later. Thirdly, patients whose cognitive function was better at 4-6 days or 3 months, when compared with baseline, did not develop cognitive dysfunction at any time point later on. In conclusion, while many patients showed a marked decline in cognitive function during the acute phase shortly after cardiac surgery, this was not associated with long-term cognitive decline. The patients who had recovered at 3 months did not develop POCD at 15 months, whereas some of those who still had POCD at 3 months had not recovered a year later, in S100b, astroglial S100 calcium-binding protein b; BFABP, brain fatty acid-binding protein; NSE, neuron-specific enolase; PfHb, plasma-free haemoglobin; Hs-TnT, high-sensitivity troponin T. PfHb, plasma-free haemoglobin; Hs-TnT, high-sensitivity Troponin T.
accordance with the literature [18] . Furthermore, there was a small group of patients who had a Z score between 0 and À2 at 3 months, but who fulfilled the criteria for POCD at 15 months. It is possible that these patients experienced an event in this one-year period that had an effect on their cognitive functions yet no data on such events were gathered. The latter may raise questions about the sensitivity of the computerised tests, but not on their specificity. However, each performance measured in the computerised testing battery was highly stable over a longer study period, indicated by a low coefficient of variation and strong test-retest reliability correlations over the course of the study year [16] . Earlier studies, involving midazolam-treated healthy volunteers [19] and a large cohort of elderly patients [16] , indicate that the battery we used was sensitive to subtle changes in cognition over time.
It can be useful, on many levels, to be able to prospectively identify patients at risk of long-term POCD. Firstly, this information could be useful during informed consent discussions between patients and their healthcare professionals. Secondly, patients with the highest risk of long-term POCD might benefit the most from neurocognitive interventions before and after cardiac surgery, which might in turn improve postoperative quality of life. Finally, this information might improve the design of future studies on the efficacy of interventions designed to prevent or treat POCD, by enabling, for example, stratified patient selection and inclusion. During future POCD studies, limiting inclusion to those patients with the highest risk could reduce the sample size necessary for future RCTs.
The bypass circuit was primed with a crystalloid and colloid solution (HAES 6%, Fresenius-Kabi, France) before use. We therefore performed a correction for plasma dilution in the analysis of the plasma samples, based on pre-and postoperative haemoglobin levels. Although not taken into account by many others, the effects of bypass and postoperative volume therapy on plasma dilution are undeniable [20] , and highly relevant in a population that includes patients who underwent surgery with cardiopulmonary bypass, as well as those who did not.
To our knowledge, this is the first study to report an association between haemolysis and post-cardiac surgery cognitive decline. We found that an increase in PfHb at sternal closure was significantly associated with POCD at 3 months. Contact of erythrocytes with the extracorporeal surfaces of the bypass machine and blood salvage systems used in cardiac surgery without bypass, can induce shear damage of the red cell membrane. Destruction of this membrane releases haem and PfHb into the plasma [21] . The normal range for PfHb is 0-20 lmol.
lÀ1
, and an increase in PfHb is indicative of haemolysis. When the severity of haemolysis surpasses the capacity of Hb-scavenging mechanisms (e.g. nitric oxide) by causing depletion, vascular endothelial cell dysfunction occurs, with subsequent production of pro-inflammatory cytokines and reactive oxygen species [22] . Lysed erythrocytes can thus affect the endothelial perivascular matrix in the brain by damaging tight junctions. A transfusion model with polymerised cell-free haemoglobin was used to prove that, after transfusions, tight junctions showed altered expression and organisation, astroglial cells were activated and diffuse iron deposition occurred in brain tissue, all of which may ultimately lead to oxidative stress and apoptosis [23] . Pathological conditions that involve chronic haemolysis, such as sickle cell disease and G6PD deficiency, are associated with impaired cognition [24] . Hence, it would be logical to assume that a temporary haemolytic state after cardiac surgery can cause temporary impairment of cognitive function such as POCD. The effects go far beyond just causing cognitive dysfunction, as a recent study showed that the release of PfHb is an independent predictor of mortality in patients undergoing extracorporeal membrane oxygenation support [25] . Haemolysis and bypass were strongly correlated in our study. However, we saw a significant increase in PfHb at sternal closure whether bypass was used or not, indicating that bypass is not the sole contributor to the increase in PfHb.
Brain fatty acid-binding protein is a 15-kDa protein specific for cerebral tissue. Following its release by astroglial cells after mechanical damage, ischaemia and oxidative brain damage, the small molecular size allows quick passage through the blood-brain barrier. Elevated BFABP concentrations in serum are not only used to detect the presence of stroke, but are also associated with a variety of other brain injury conditions, such as mild traumatic brain injury and electroconvulsive therapy. Healthy elderly individuals usually have BFABP plasma levels < 5 pg.ml
À1
, whereas BFABP in patients with Alzheimer's disease, Parkinson's disease or other neurocognitive disorders usually ranges between 10-20 pg.ml À1 [26] . This corresponds with our findings, as patients with POCD at 15 months had a higher BFABP plasma level at baseline, which increased after 24 h and remained significantly higher than in patients who did not develop POCD later. Interestingly, our population was selected for not having neuropsychological defects before surgery. This suggests that BFABP can possibly identify patients who are vulnerable to the development of POCD, even though they do not have any pre-operative signs of (mild) cognitive impairment [27] . Neuron-specific enolase is a glycolytic enzyme that catalyses the conversion of 2-phosphoglycerate to phosphoenolpyruvate. As the name suggests, NSE is mainly present in neuronal and neuroendocrine tissues. Release in the serum is considered to identify neuronal destruction, as elevated levels of the protein are found in patients after traumatic brain injury [28] . However, haemolysis itself can lead to significant artificial NSE elevations, since erythrocytes also contain NSE [29] . This might explain the rise in NSE levels seen in the samples taken at sternal closure in patients who underwent surgery with bypass [28] . The increase in NSE in plasma during and immediately after bypass was in accordance with the literature [30] . However, we did not find an association between increased NSE at sternal closure and POCD [13] .
The reason for a possible association between raised plasma S100b levels and POCD is not clear. Astroglial S100 calcium-binding protein b is a marker for traumatic brain injury that is expressed by mature astroglial cells in the central nervous system and by Schwann cells in the peripheral nervous system. In the developing nervous system, S100b acts as a neurotrophic factor with major functions related to neuronal survival, neurite extension, axonal proliferation and stimulation of Ca 2+ -fluxes [31] . In the mature brain, the expression of the protein is upregulated mainly after neuronal damage. Significant elevations of serum S100B levels are found in patients who have suffered from severe traumatic brain injury, neurological complications after surgery and POCD [31] . Similarly to NSE, release into plasma is rapid, which makes the marker ideal for investigation of brain injury in an acute setting [28, 31] . Interestingly, others have pointed out that lower plasma S100b levels are associated with cognitive impairment [12] . This ambiguous relationship was present in our data set, as patients who developed POCD had high initial S100b levels, whereas patients who did not develop POCD had higher S100b levels 24 h after surgery. Problems regarding the interpretation and variability in plasma levels of S100b can be attributed to release patterns of S100b after cardiac surgery [32] . This implies that multiple samples would need to be analysed to gather enough information to render a reliable estimation for development of POCD, which makes it costlier and less efficient as a predictive biomarker. Lack of POCD can be described as a surrogate marker for general wellbeing. We established that postoperative mortality correlated with the Z-score patients achieved at the three-month time-point. These results are in accordance with earlier findings on the subject [1] .
Long-term followup of cognitive function is limited by the fact that patients are subjected not only to surgery but also to natural memory decline over time. However, the change scores that were calculated from the results of the computerised testing battery we used, were standardised according to normative test-retest variability data from age-matched controls. An additional limitation of this study is the small sample size, which was limited by the sample size of the primary randomised, controlled trial.
In conclusion, cognitive dysfunction established at 3 months after coronary artery surgery, beyond the acute phase, serves as a valuable prognostic factor for ongoing individual cognitive decline a year later. We also found a clear association between POCD at 3 months and postoperative mortality. Classical neuronal injury-related biomarkers did not have clear prognostic value in our study population. However, PfHb at sternal closure and hs-TnT measured within one day after surgery as a measure of myocardial injury, were significantly associated with long-term cognitive dysfunction. The relevance of our results lies in their hypothesis-generating properties. Further studies might support these findings, and help to identify which patients benefit the most from neurocognitive and other interventions aimed at general health improvement, and help researchers to improve selection criteria for patient inclusion in studies investigating POCD.
